Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Immune-associated ALS
NCT04952155Phase 2Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in amyotrophic lateral sclerosis (ALS), sponsored by Peking University Third Hospital. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04952155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952155.